Affirming support for most-favored-Nation drug pricing for United States patients.

HRES 928 is a non-binding House resolution affirming support for aligning U.S. prescription drug prices with those in other developed nations, commonly called "most-favored-nation" pricing. It states that U.S. patients should not pay more for the same drugs than citizens in comparable countries, citing data showing U.S. drug prices are 2.78 times higher than in other nations and that 21% of adults skip prescriptions due to cost. The resolution supports policies to reduce drug costs, including aligning U.S. pricing with international benchmarks and expanding Medicare negotiation, but does not create new laws or alter existing programs. It directly addresses all U.S. patients affected by high drug costs, reflecting bipartisan interest in lowering prices as noted in President Trump’s 2025 executive order.